Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSEARCA:AOR NASDAQ:AREC NASDAQ:OKYO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAORiShares Core 60/40 Balanced Allocation ETF$63.01+0.3%$61.74$52.97▼$63.08$2.63B0.61251,411 shs257,621 shsARECAmerican Resources$2.09-4.1%$1.28$0.38▼$2.49$184.45M0.894.67 million shs5.09 million shsOKYOOKYO Pharma$2.28+0.9%$2.70$0.90▼$3.35$85M-0.09195,650 shs44,255 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAORiShares Core 60/40 Balanced Allocation ETF-0.02%+0.61%+1.68%+5.52%+7.99%ARECAmerican Resources+3.81%+65.15%+80.17%+225.42%+296.80%OKYOOKYO Pharma-5.44%-8.13%-17.22%+20.86%+107.34%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAORiShares Core 60/40 Balanced Allocation ETFN/AN/AN/AN/AN/AN/AN/AN/AARECAmerican Resources2.9638 of 5 stars3.54.00.00.03.10.80.6OKYOOKYO Pharma3.141 of 5 stars3.55.00.00.03.31.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAORiShares Core 60/40 Balanced Allocation ETF 0.00N/AN/AN/AARECAmerican Resources 3.00Buy$4.0091.39% UpsideOKYOOKYO Pharma 3.00Buy$7.00207.02% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAORiShares Core 60/40 Balanced Allocation ETFN/AN/AN/AN/AN/AN/AARECAmerican Resources$330.30K535.36N/AN/A($1.09) per share-1.92OKYOOKYO PharmaN/AN/AN/AN/A($0.16) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAORiShares Core 60/40 Balanced Allocation ETFN/AN/A19.83∞N/AN/AN/AN/AN/AARECAmerican Resources-$40.11M-$0.49N/A34.83N/A-13,152.00%N/A-21.17%11/13/2025 (Estimated)OKYOOKYO Pharma-$4.71MN/A0.00N/AN/AN/AN/AN/AN/ALatest HEMO, AREC, OKYO, and AOR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/19/2025Q2 2025ARECAmerican Resources-$0.05-$0.10-$0.05-$0.10$16.40 million$0.01 million6/10/2025Q4 2024ARECAmerican Resources-$0.05-$0.24-$0.19-$0.24$1.30 million$0.05 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAORiShares Core 60/40 Balanced Allocation ETF$1.592.52%N/AN/AN/AARECAmerican ResourcesN/AN/AN/AN/AN/AOKYOOKYO PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAORiShares Core 60/40 Balanced Allocation ETFN/AN/AN/AARECAmerican ResourcesN/A0.120.10OKYOOKYO PharmaN/A0.400.40Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAORiShares Core 60/40 Balanced Allocation ETFN/AARECAmerican Resources9.32%OKYOOKYO Pharma2.97%Insider OwnershipCompanyInsider OwnershipAORiShares Core 60/40 Balanced Allocation ETFN/AARECAmerican Resources16.80%OKYOOKYO Pharma40.46%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAORiShares Core 60/40 Balanced Allocation ETFN/A41.75 millionN/ANot OptionableARECAmerican Resources1084.61 million70.40 millionOptionableOKYOOKYO Pharma737.61 million22.39 millionNot OptionableHEMO, AREC, OKYO, and AOR HeadlinesRecent News About These CompaniesOKYO Pharma (NASDAQ:OKYO) Raised to "Hold" at Wall Street ZenAugust 10, 2025 | marketbeat.comNeuropathic corneal pain reduced in phase 2 trial of urcosimodAugust 7, 2025 | healio.comHDauntless Investment Group LLC Invests $2.53 Million in OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO)July 29, 2025 | marketbeat.comOKYO Pharma CEO details positive results from Phase 2 urcosimod trial - ICYMIJuly 19, 2025 | proactiveinvestors.comOKYO Pharma CEO details positive results from Phase 2 urcosimod trial - ICYMIJuly 19, 2025 | proactiveinvestors.comOKYO Slides Despite Fresh R&D FundingJuly 17, 2025 | baystreet.caOKYO Pharma Receives $1.9 Million in Non-Dilutive Funding to Accelerate Development of Urcosimod for Neuropathic Corneal PainJuly 17, 2025 | finance.yahoo.comOKYO Pharma Secures $1.9 Million to Boost Urcosimod DevelopmentJuly 17, 2025 | tipranks.comOKYO Pharma secures $1.9M in non-dilutive funding to advance clinical development of NCP therapyJuly 17, 2025 | proactiveinvestors.comOKYO reports top-line data from neuropathic corneal pain therapy trialJuly 17, 2025 | finance.yahoo.comOkyo sets sights on first approval in neuropathic eye pain after phase 2 winJuly 16, 2025 | fiercebiotech.comFOKYO Pharma shares surge following promising Phase 2 data for eye pain treatmentJuly 16, 2025 | msn.comPositive Buy Rating for OKYO Pharma Driven by Promising Phase 2 Trial Results and FDA Fast Track DesignationJuly 16, 2025 | tipranks.comOKYO Pharma Reports Promising Phase 2 Results for Urcosimod in Treating Neuropathic Corneal PainJuly 16, 2025 | tipranks.comOKYO Pharma reports positive Phase 2 results for urcosimod in neuropathic corneal painJuly 16, 2025 | proactiveinvestors.comOKYO Pharma Unveils Strong Phase 2 Clinical Trial Results for Urcosimod to Treat Neuropathic Corneal PainJuly 16, 2025 | globenewswire.comOKYO Pharma Limited's (NASDAQ:OKYO) market cap up US$38m last week, benefiting both individual investors who own 58% as well as insidersJune 14, 2025 | uk.finance.yahoo.comOKYO Pharma to Present at the Bio International ConventionJune 11, 2025 | manilatimes.netMOKYO Pharma poised for breakout as Phase 2 trial nears results: analystsJune 11, 2025 | proactiveinvestors.comGoldman Small Cap Research Issues New Research Update on OKYO Pharma Limited | OKYO Stock NewsJune 11, 2025 | gurufocus.comGoldman Small Cap Research Issues New Research Update on OKYO Pharma LimitedJune 11, 2025 | accessnewswire.comANew MarketBeat Followers Over TimeMedia Sentiment Over TimeHEMO, AREC, OKYO, and AOR Company DescriptionsiShares Core 60/40 Balanced Allocation ETF NYSEARCA:AOR$63.01 +0.17 (+0.27%) Closing price 04:10 PM EasternExtended Trading$63.04 +0.02 (+0.04%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.iShares Growth Allocation ETF, formerly iShares S&P Growth Allocation Fund (the Fund), is an open-end management investment company. The Fund seeks investment results that correspond generally to the price and yield performance of the S&P Target Risk Growth Index (the Growth Allocation Index). The Growth Allocation Index seeks to measure the performance of an asset allocation strategy targeted to a growth-focused risk profile. The Fund is designed for investors seeking moderate capital appreciation and opportunity for current income and capital preservation. The Fund's investment advisor is BlackRock Fund Advisors.American Resources NASDAQ:AREC$2.09 -0.09 (-4.13%) Closing price 04:00 PM EasternExtended Trading$2.08 0.00 (-0.24%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.American Resources Corporation, together with its subsidiaries, extracts, processes, transports, and sells metallurgical coal to the steel and industrial industries. It supplies raw materials; and sells coal used in pulverized coal injections. The company was founded in 2006 and is headquartered in Fishers, Indiana.OKYO Pharma NASDAQ:OKYO$2.28 +0.02 (+0.88%) Closing price 03:59 PM EasternExtended Trading$2.28 0.00 (-0.22%) As of 04:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor NVIDIA Stock Could Pull Back in September, But Don’t Bet on It NIO Just Got Its Second Upgrade of the Month, and It’s Big Chevron Stock Outlook: Dividend Growth Meets Inflation As Bitcoin Falls and Ethereum Rallies, Coinbase Stock Comes Back Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access